

Placental Tissue Matrix
Skye Biologics PX50®

Case Report
June 3, 2016

Shawn Tierney, DC, RSMK Musculoskeletal Sonologist
Carol Hanselman, RNP
Rome Walter, DO

Diagnosis

Low Back Pain, Lumbar Facet Joint Capsulitis and Hypertrophy at L4-L5

Intro

On May 25, 2016, an athletic 37-year-old male presented with three years of severe low back pain. He had been competing in professional Jiu Jitsu for years, and felt more pain in the morning after workouts. Every morning, it took him 20 minutes each morning to stretch his hips, back, and legs, in order to walk. He was concerned he would not be able to continue competing in Jiu Jitsu if he didn't find a way fix his back.

Patient was examined by Shawn Tierney, DC, RSMK Musculoskeletal Sonologist, using a GE R6 B-mode ultrasound using 8 to 13MHz high frequency GE 12L linear transducer and a 2 to 5.3MHz 4C curvilinear transducer. His ultrasound exam revealed lumbar facet joint hypertrophy, effusion and capsulitis at L4-L5.

Treatment

For diagnostic confirmation, 0.5 cc .5% Ropivacaine was injected into each of the bilateral facet joints of L4 and L5 of the patient's low back. One minute after the

injection, patient was able to squat and bend without pain. These were the intended effects of the Ropivacaine nerve block: to confirm the precise location of the arthritis and to block the sympathetic-mediated or 'learned' pain.

With assurance of the precise joints, the PX50® was prepared for administration. 0.5 cc .5% Ropivacaine was mixed with 0.5 cc Skye Biologics Placental Tissue Matrix Allograft, PX50® and injected into the bilateral facet joints of L4 and L5 of the patient's low back. The goal was to provide sustaining regeneration to the patient's low back and to prevent further degeneration of L4-L5.

Follow-up

While the patient initially reported a flare-up of pain in his back on the 2nd and 3rd days after the injection, this pain diminished by the end of the first week. Moreover, six weeks after the injection, the patient reported major relief. He was able to complete daily Jiu Jitsu workouts without taking Motrin, and he reported having no sustaining pain after each workout. His pain was currently at a level of 3/10. Upon ultrasound examination, the lumbar facet joint capsulitis L4-L5 was improving, with significantly less irregularity, and no residual effusion. Patient was given clearance to complete in the upcoming week in the National Jiu Jitsu Championship. Because of the PX50® injection, patient believed that his performance at the National Championship would not merely be possible, but most likely victorious.

Figure 1. Reduction in Self-Reported Pain on a 1-10 Scale, before and after PTM Placental Tissue Matrix

Level of Pain	Pre- PX50®	Post- PX50®
	7/6/16	8/8/16
Average Pain	3	0
% Reduction in Pain	100%	